Bonafide Women’s Health Acquires SAM-e Formulation With High Bioavailability

Women’s health company acquired patent for SAM-e formulation MSI-195 after innovator's study showed it had nearly three times higher availability than a leading competitor.

• Source: Alamy (Alamy Stock Photo)

Bonafide Women’s Health LLC recently added to its more than 50 women’s health supplement formulations by acquiring a proprietary SAM-e ingredient from Canadian firm MSI Methylation Sciences Inc.

MSI Methylation sold its S-adenosyl-L-methionine ingredient, a controlled-release tablet identified as MSI-195, after conducting a study on its safety and...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Ingredients & Safety

More from HBW Insight